For ALK positive NSCLC, where in treatment sequencing do you utilize lorlatinib?
1
1 Answers
Mednet Member
Medical Oncology · Henry Ford Cancer Institute/Henry Ford Hospital
The CROWN trial was one of the most important trials reported in the field of lung cancer in 2020. The results of this trial with a median follow up of 18 months were presented by Dr. Ben Solomon at ESMO 2020. The HR for Investigator assessed PFS in this trial with lorlatinib was 0.21 (0.28- Indepen...